A large new analysis of UK Biobank participants ties daily coffee to noticeably lower chances of severe liver problems, liver cancer and liver-related death, and it backs those numbers with imaging and blood-marker findings that point to biological effects beyond just statistics.
The study followed 354,957 people who started out without cirrhosis or liver cancer, tracking health outcomes for about 13 years on average. Researchers used self-reported coffee habits recorded at baseline and then linked those habits to long-term liver outcomes in the dataset. That long follow-up makes the associations harder to ignore, even if it cannot fully prove cause and effect.
Drinking one to two cups a day was associated with a roughly 20% lower chance of developing cirrhosis and a 31% lower risk of dying from liver-related causes compared with people who did not drink coffee. Those are substantial relative reductions at a modest consumption level, and they held up after accounting for several common risk factors. The pattern suggests a real, measurable relationship between routine coffee intake and better liver outcomes.
Benefits increased with higher consumption. People who reported five or more cups per day showed about a 32% drop in cirrhosis risk, a 42% lower risk of liver-related death and a 47% reduced risk of hepatocellular carcinoma, which is the most common primary liver cancer. Those larger differences point to a dose-response pattern, where more coffee corresponded with stronger associations in the data.
ZERO SUGAR, MORE PROBLEMS? STUDY REVEALS SURPRISING GUT HEALTH EFFECTS
The team dug deeper into why coffee might be protective by analyzing imaging data from nearly 29,000 participants and blood markers from roughly 50,000 people in the cohort. Imaging showed that heavier coffee drinkers tended to have less liver fat and lower liver iron, and they had reduced odds of fibroinflammation, the scarring and inflammatory changes that often lead to permanent damage. Those objective measures lend biological plausibility to the epidemiological findings.
Blood analyses reinforced the imaging results, revealing lower levels of certain proteins linked to inflammation and scarring among regular coffee drinkers and higher levels of proteins tied to normal liver function. In other words, the beverage profile matched the healthier liver picture seen on scans. That alignment between labs and images makes the association feel more than just a statistical fluke.
Importantly, the apparent protective signal was similar for caffeinated and decaffeinated coffee, which suggests the benefits come from compounds in coffee other than caffeine. How you take your coffee mattered a bit: adding sugar or artificial sweeteners seemed to blunt the effect, especially for markers linked to liver inflammation. So plain coffee or minimally sweetened coffee appears to carry most of the benefit in this dataset.
Prior research has hinted at a positive link between coffee and liver health, but this investigation adds depth by pairing long-term outcomes with imaging and blood chemistry. Still, it remains an observational study based on self-reported diet, so changes in drinking habits over the 13-year follow-up could influence results. Confounding factors may also play a role, which means the analysis can show strong correlations but cannot definitively prove causation.
The practical takeaway is that coffee could be a simple, accessible habit that aligns with better liver markers and lower observed rates of severe liver disease, but it should not replace standard preventive care. Clinical screening, vaccines where appropriate, limiting excess alcohol and working with a provider on metabolic risks remain the backbone of liver protection. For people who enjoy coffee, these findings add another reason to sip thoughtfully and avoid piling on sugar and artificial sweeteners.
